Medical Hypotheses
Volume 61, Issue 3 , Pages 335-339 , September 2003

Estrogen agonists/antagonists may down-regulate growth hormone signaling in hepatocytes–An explanation for their impact on IGF-I, IGFBP-1, and lipoprotein(a)

  • Mark F McCarty

      Affiliations

    • Corresponding Author InformationCorrespondence to: Mark F. McCarty, Present address: NutriGuard Research, 1051 Hermes Ave., Encinitas, CA 92024, USA

Received 27 July 2001 ,Accepted 19 December 2001.

References 

  1. Kelly JJ, Rajkovic IA, O’Sullivan AJ, Sernia C, Ho KK. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin. Endocrinol. (Oxf). 1993;39:561–567
  2. Campagnoli C, Biglia N, Peris C, Sismondi PX. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol. Endocrinol. 1995;9:67–74
  3. Helle SI, Omsjo IH, Hughes SQ, et al.  Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin. Endocrinol. (Oxf). 1996;45:727–732
  4. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 1997;17:1822–1829
  5. Mijatovic V, Kenemans P, Netelenbos JC, et al.  Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 1997;82:3543–3547
  6. Paassilta M, Karjalainen A, Kervinen K, et al.  Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis. 2000;149:157–162
  7. Loaning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992;52:4719–4723
  8. Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur. J. Cancer A. 1993;29:1368–1372
  9. Ho GH, Ji CY, Phang BH, Lee KO, Soo KC, Ng EH. Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study. Ann. Surg. Oncol. 1998;5:361–367
  10. Reed MJ, Christodoulides A, Koistinen R, Seppala M, Teale JD, Ghilchik MW. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int. J. Cancer. 1992;52:208–212
  11. Lahti EI, Knip M, Laatikainen TJ. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer. 1994;74:618–624
  12. Shewmon DA, Stock JL, Rosen CJ, et al.  Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler. Thromb. 1994;14:1586–1593
  13. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol. 1996;14:429–433
  14. Zysow BR, Kauser K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen., and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 1997;17:1741–1745
  15. Decensi A, Robertson C, Ballardini B, et al.  Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur. J. Cancer. 1999;35:596–600
  16. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm. Res. 1999;51(Suppl. 3):34–41
  17. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur. J. Cancer. 2000;36:1224–1228
  18. McCarty MF. Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. Med. Hypotheses. 1997;48:297–308
  19. Scanu AM. Atherothrombogenicity of lipoprotein(a): the debate. Am. J. Cardiol. 1998;82:26Q–33Q
  20. Seman LJ, McNamara JR, Schaefer EJ. Lipoprotein(a), homocysteine, and remnant like particles: emerging risk factors. Curr. Opin. Cardiol. 1999;14:186–191
  21. Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm. Res. 1994;42:145–151
  22. Kachra Z, Yang CR, Murphy LJ, Posner BI. The regulation of insulin-like growth factor-binding protein 1 messenger ribonucleic acid in cultured rat hepatocytes: the roles of glucagon and growth hormone [see comments]. Endocrinology. 1994;135:1722–1728
  23. Hu M, Robertson DG, Murphy LJ. Growth hormone modulates insulin regulation of hepatic insulin-like growth factor binding protein-1 transcription. Endocrinology. 1996;137:3702–3709
  24. Lu X, Shi Z, Murphy LJ. Growth hormone suppression of insulin-like growth factor binding protein-1 promoter activity. Mol. Cell. Endocrinol. 1999;149:19–28
  25. Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med. 1997;216:319–357
  26. Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc. Soc. Exp. Biol. Med. 1993;204:4–29
  27. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein(a) in man. J. Clin. Invest. 1980;65:1483–1490
  28. Lam KS, Pang RW, Janus ED, Kung AW, Wang CC. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis. 1993;104:183–188
  29. Oscarsson J, Wiklund O, Jakobsson KE, Petruson B, Bengtsson BA. Serum lipoproteins in acromegaly before and 6–15 months after transsphenoidal adenomectomy. Clin. Endocrinol. (Oxf). 1994;41:603–608
  30. Wildbrett J, Hanefeld M, Fucker K, et al.  Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp. Clin. Endocrinol. Diabetes. 1997;105:331–335
  31. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group [in process citation]. Atherosclerosis. 2000;151:551–557
  32. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler. Thromb. 1993;13:296–301
  33. Mooser V, Hobbs HH. Lipoprotein(a) and growth hormone: is the puzzle solved? [see comments]. Eur. J. Endocrinol. 1997;137:450–452
  34. Laron Z, Wang XL. Growth hormone, lipoprotein(a) and cardiovascular disease. Eur. Heart J. 1998;19:204–206
  35. Laursen T, Lemming L, Jorgensen JO, Klausen IC, Christiansen JS. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients. Horm. Res. 1998;50:284–291
  36. Bianda T, Schmid C. Effects of short-term treatment with insulin-like growth factor-I and growth hormone on serum lipoprotein(a) in growth hormone-deficient adults [letter; comment]. Eur. J. Endocrinol. 1998;138:189–190
  37. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Insulin-like growth factor-I decreases serum lipoprotein(a) during long-term treatment of patients with Laron syndrome. Metabolism. 1996;45:1263–1266
  38. Tao R, Acquati F, Marcovina SM, Hobbs HH. Human growth hormone increases apo(a) expression in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 1999;19:2439–2447
  39. Frazer KA, Narla G, Zhang JL, Rubin EM. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat. Genet. 1995;9:424–431
  40. Acquati F, Hammer R, Ercoli B, et al.  Transgenic mice expressing a human apolipoprotein[a] allele. J. Lipid Res. 1999;40:994–1006
  41. Yu YM, Domene HM, Sztein J, Counts DR, Cassorla F. Developmental changes and differential regulation by testosterone and estradiol of growth hormone receptor expression in the rabbit. Eur. J. Endocrinol. 1996;135:583–590
  42. Gabrielsson BG, Carmignac DF, Flavell DM, Robinson IC. Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology. 1995;136:209–217
  43. Bennett PA, Levy A, Carmignac DF, Robinson IC, Lightman SL. Differential regulation of the growth hormone receptor gene: effects of dexamethasone and estradiol. Endocrinology. 1996;137:3891–3896
  44. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J. Clin. Endocrinol. Metab. 1999;84:3956–3960
  45. Campagnoli C, Biglia N, Cantamessa C, Di Sario MM, Lesca L. Effect of progestins on IGF-I serum level in estrogen-treated postmenopausal women. Zentralbl. Gynakol. 1997;119(Suppl. 2):7–11
  46. Campagnoli C, Biglia N, Cantamessa C, Lesca L, Sismondi P. HRT and breast cancer risk: a clue for interpreting the available data [in process citation]. Maturitas. 1999;33:185–190
  47. Heald A, Selby PL, White A, Gibson JM. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am. J. Obstet. Gynecol. 2000;183:593–600
  48. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis. 1996;122:89–95
  49. Zmunda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. Am. J. Cardiol. 1996;77:1244–1247
  50. Berglund L, Carlstrom K, Stege R, et al.  Hormonal regulation of serum lipoprotein(a) levels: effects of parenteral administration of estrogen or testosterone in males. J. Clin. Endocrinol. Metab. 1996;81:2633–2637
  51. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med. 1999;106:574–582
  52. Paganini-Hill A. Estrogen replacement therapy and colorectal cancer risk in elderly women. Dis. Colon Rectum. 1999;42:1300–1305
  53. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253–260
  54. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comments]. JAMA. 2000;283:485–491
  55. Rickard SE, Yuan YV, Thompson LU. Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside. Cancer Lett. 2000;161:47–55
  56. Jenkins DJ, Kendall CW, Vidgen E, et al.  Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am. J. Clin. Nutr. 1999;69:395–402
  57. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr. 1999;129:1628–1635

PII: S0306-9877(02)00215-3

doi: 10.1016/S0306-9877(02)00215-3

Medical Hypotheses
Volume 61, Issue 3 , Pages 335-339 , September 2003

Article Tools